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four weeks of treatment. Thus, TCP once daily is the most
cost-effective treatment regime. In addition, when com-
paring current treatment practice (twice daily calcipotriol
applied for 8 weeks) to the once daily application of the
TCP for 4 weeks, it will reduce the treatment cost for pso-
riasis in Sweden by 46.2%. CONCLUSION: This study
demonstrates that TCP applied once daily is both cost-
effective and a cost-minimising treatment strategy, which
offers psoriasis patients a convenient and highly effective
treatment regime with a rapid onset of action.
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Despite longstanding use of Methotrexate (MTX) and
Cyclosporin A (CsA) in patients with severe psoriasis,
true comparative evidence derived from a RCT evaluat-
ing these systemic therapies was still lacking. Our
prospective, double blinded randomised comparison of
16 weeks treatment with MTX or CsA in 85 patients
showed comparable effectiveness and quality of life 
(Heydendael, submitted). The question arises, whether
other aspects, including costs of treatment of psoriasis,
side effects of subjective perspectives could be deciding
factors in treatment decision making; especially consider-
ing the different retail prices for MTX and CsA. OBJEC-
TIVES: To document the process of treatment of psoriasis
with MTX or CsA and follow-up in terms of resource
utilisation and associated costs. METHODS: Additional
data on direct medical and nonmedical costs and indirect
costs were collected for all 85 randomised patients up 
to 1 year after randomisation, and a cost minimisation
analysis was set up according to a societal perspective.
RESULTS: The average cumulative costs associated with
16 weeks treatment was €1,593 in MTX and €2,113 in
CsA (€520 difference favouring MTX), whereas 36 weeks
of follow up generated €2,417 (MTX) and €2,306 (CsA)
(difference: €111 in favour of CsA). Overall costs after
one year lead to an overall difference of €409 in favour
of MTX on a total cost of €4010 (10%). CONCLU-
SIONS: Economic arguments are not a deciding factor in
decision making between MTX or CsA for treatment of
severe psoriasis, as differences are small and costs associ-
ated with treatment and follow up management are gen-
erated by a variety of resources utilised, than costs of
systemic therapy alone.
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OBJECTIVES: The purpose of the evaluation is to show
the resource utilization and related costs per year as well
as per ﬂare for patients suffering from atopic dermatitis
in Switzerland from patients’ and third-party payers’ per-
spective. METHODS: Multi-center, retrospective cost-of-
illness study. Information as demographic characteristics,
number of ﬂares per year, consultations, hospitalizations,
cures and out-of-pocket expenditures as for e.g. OTC-
medication was collected with a patient-questionnaire.
Resource utilization of outpatient care was gained from
patient’s records. Direct and indirect costs were consid-
ered. RESULTS: Three ofﬁce-based pediatricians, two
ofﬁce-based dermatologists and two dermatology hospi-
tals participated. Sixty-ﬁve patients are included in this
study until now. Thirty-four patients sent back the ques-
tionnaire (52%). Mean age of patients is 17 years (1–70
years); about 42% are female. About 34% of the patients
have a mild course of disease; about 36% suffer from 
a moderate and 30% from a severe or extreme severe
course of disease. On average, 4.0 (SD 3.7) ﬂares per year
were reported by the patients. Two out of 31 patients
(6.5%) require hospitalization due atopic dermatitis per
year. From the patients’ perspective the main cost drivers
are OTC-medication and skin care products with annual
costs of CHF 360 per patient. Patients’ expenses for
special investigations and other devices for e.g. special
clothes and nutrition are about CHF 355 per patient. 
For additional treatment (e.g. psychotherapeutics and/or
naturopathy) patients spent about CHF 85 per year.
CONCLUSION: These preliminary results show that out-
of-pocket expenses per patient and year amount about
CHF 800. The study is still ongoing and ﬁnal cost data
from the third party payers’ perspective are under evalu-
ation until August 2002.
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OBJECTIVES: To estimate the resource utilization and
related costs per ﬂare and per year for patients suffering
from atopic dermatitis in Germany from patients’ and 
the third-party payers’ perspective. METHODS: Multi-
